<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191541</url>
  </required_header>
  <id_info>
    <org_study_id>CCAPL2010</org_study_id>
    <nct_id>NCT01191541</nct_id>
  </id_info>
  <brief_title>Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)</brief_title>
  <acronym>Ara-C</acronym>
  <official_title>Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia in Children: Remission Induction With All-transretinoic Acid (ATRA) and Arsenic Trioxide (As2O3). Consolidation With Daunorubicin(DNR)+Ara-c or DNR Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaofan Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low&#xD;
      relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining&#xD;
      ll-transretinoic acid (ATRA) and anthracyclines without Ara-C, suggesting that avoiding Ara-C&#xD;
      in the chemotherapy of APL reduced treatment toxicity without increasing relapses. While the&#xD;
      relapse rate for the children with white blood cell(WBC) counts greater than 10×109/L at&#xD;
      presentation were higher than those WBC counts less than 10×109/L (31% and 3.5%,respectively)&#xD;
      in the LPA96 and 99 trials. A recent adult randomized trial show that avoiding Ara-C leads to&#xD;
      an increased risk of relapse in the APL patients with WBC counts less than 10×109/L. The role&#xD;
      of the Ara-C remains controversial. And there are very limited data reported on children with&#xD;
      APL so far.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some studies suggest patients with high-risk disease should be treated with intensified doses&#xD;
      of anthracycline, or intermediate/ high-dose Ara-C or As2O3 as an early consolidation, so as&#xD;
      to decrease the risk of relapse.However, a higher cumulative dose of anthracycline may lead&#xD;
      to cardiac toxicity, especially for children. In addition, containing Ara-C will led to more&#xD;
      therapy-related toxicity. The benefit to add Ara-C to the schedules is questionable and&#xD;
      remains a matter of investigation in children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial</measure>
    <time_frame>two years</time_frame>
    <description>We assessed the OS of APL patients when ATRA and ATO were used. The overall survival (OS) durations was calculated from the date of diagnosis to last follow-up or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial</measure>
    <time_frame>2 years</time_frame>
    <description>We assessed the EFS of APL patients treated with retinoic acid receptor alpha (ATRA) and Arsenic Trioxide (ATO) based trial. Event-free survival (EFS) was defined as time from diagnosis to last follow-up or an event (relapse or death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Side Effects</measure>
    <time_frame>three years</time_frame>
    <description>Also, we compared the side effect and outcome between the two groups.To assessed whether Ara-C could be omitted when ATO and ATRA were used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>DNR+Ara-c(Ara-C group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group were treated with DNR+Ara-C in consolidation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DNR(No Ara-C group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this group were treated with DNR alone in consolidation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNR:</intervention_name>
    <description>DNR：45mg/m2 d1-3</description>
    <arm_group_label>DNR(No Ara-C group)</arm_group_label>
    <arm_group_label>DNR+Ara-c(Ara-C group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-c</intervention_name>
    <description>DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3</description>
    <arm_group_label>DNR+Ara-c(Ara-C group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute Promyelocytic Leukemia (APL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt; 14&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofan Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodríguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, González JD, Bolufer P, González M, Sanz MA; PETHEMA Group. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005 Oct 20;23(30):7632-40.</citation>
    <PMID>16234524</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <results_first_submitted>February 6, 2017</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Xiaofan Zhu</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>ara-c</keyword>
  <keyword>As2O3</keyword>
  <keyword>pediatric</keyword>
  <keyword>acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 20, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01191541/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01191541/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible patients were those who were less than 14 years old, were newly diagnosed with APL, and had not previously received chemotherapy. Sixty-five patients were included in the study.</recruitment_details>
      <pre_assignment_details>The demonstration of PML-RARA transcripts, was required for inclusion in the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Daunorubicin(DNR)+Ara-c (Ara-C Group)</title>
          <description>one group treated with daunorubicin(DNR)+Ara-C in consolidation</description>
        </group>
        <group group_id="P2">
          <title>DNR (No Ara-c Group)</title>
          <description>Only DNR was used in consolidation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>All the Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>the Randomized Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DNR+Ara-c</title>
          <description>one group treated with DNR+Ara-C</description>
        </group>
        <group group_id="B2">
          <title>DNR（ no Ara-C)</title>
          <description>one group treated with DNR</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="2" upper_limit="13"/>
                    <measurement group_id="B2" value="7" lower_limit="2" upper_limit="14"/>
                    <measurement group_id="B3" value="8" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Eligible patients were less than 14 years of age with newly diagnosed APL without chemotherapy used before. Molecular diagnosis was not required for enrollment, but subsequent molecular confirmation by demonstration of promyelocytic leukemia(PML)-retinoic acid receptor alpha(RARA)（PML-RARA） transcripts was required for inclusion in the analysis. A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of polymerase-chain-reaction (PCR) assay</description>
          <population>Between May 2010 and December 2016, 65 consecutive patients with genetically confirmed newly diagnosed APL patients (≤14years) were admitted in our hospital.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>white blood cell count</title>
          <units>cells x 10^9/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.23" lower_limit="0.99" upper_limit="130"/>
                    <measurement group_id="B2" value="5.47" lower_limit="0.82" upper_limit="202.4"/>
                    <measurement group_id="B3" value="4.71" lower_limit="0.82" upper_limit="202.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Haemoglobin</title>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" lower_limit="44" upper_limit="124"/>
                    <measurement group_id="B2" value="81.0" lower_limit="49" upper_limit="127"/>
                    <measurement group_id="B3" value="78" lower_limit="44" upper_limit="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count</title>
          <units>cells x 10^9/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" lower_limit="2" upper_limit="125"/>
                    <measurement group_id="B2" value="32.0" lower_limit="6" upper_limit="130"/>
                    <measurement group_id="B3" value="30.5" lower_limit="2" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial</title>
        <description>We assessed the OS of APL patients when ATRA and ATO were used. The overall survival (OS) durations was calculated from the date of diagnosis to last follow-up or death.</description>
        <time_frame>two years</time_frame>
        <population>There were 65 patients included in our study, including 35 in the DNR group and 30 in the DNR+Ara-C group.</population>
        <group_list>
          <group group_id="O1">
            <title>DNR Group</title>
            <description>the patients in this group were treated with DNR alone in consolidation</description>
          </group>
          <group group_id="O2">
            <title>DNR+Ara-C Group</title>
            <description>the patients in this group were treated with DNR +Ara-C in consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial</title>
          <description>We assessed the OS of APL patients when ATRA and ATO were used. The overall survival (OS) durations was calculated from the date of diagnosis to last follow-up or death.</description>
          <population>There were 65 patients included in our study, including 35 in the DNR group and 30 in the DNR+Ara-C group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The characteristics of all of the included patients were summarized using cross-tabulations (for categorical variables) and quantiles. Nonparametric tests were used to analyse comparisons between groups .EFS、disease-free survival (DFS) and OS were estimated using the Kaplan -Meier method, and log-rank tests were used. All P values were two-sided, and those with values of 0.05 or less were considered to be statistically significant.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The primary objective was to demonstrate the noninferiority of DNR alone to DNR+ARA-C in the rate of DFS at 2 years. Assuming a 95% rate of DFS in the two groups, a margin of -15% , 5% type 1 error, 80% power, 30 evaluable patients per group were required to draw a noninferiority conclusion.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>the p-value is not adjusted</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial</title>
        <description>We assessed the EFS of APL patients treated with retinoic acid receptor alpha (ATRA) and Arsenic Trioxide (ATO) based trial. Event-free survival (EFS) was defined as time from diagnosis to last follow-up or an event (relapse or death).</description>
        <time_frame>2 years</time_frame>
        <population>There were 65 patients included in our study, including 35 in the DNR group and 30 in the DNR+Ara-C group.</population>
        <group_list>
          <group group_id="O1">
            <title>DNR+Ara-c(Ara-C Group)</title>
            <description>patients in this group were treated with DNR+Ara-C in consolidation&#xD;
DNR:: DNR：45mg/m2 d1-3&#xD;
Ara-c: DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3</description>
          </group>
          <group group_id="O2">
            <title>DNR(No Ara-C Group)</title>
            <description>patients in this group were treated with DNR alone in consolidation&#xD;
DNR:: DNR：45mg/m2 d1-3</description>
          </group>
        </group_list>
        <measure>
          <title>the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial</title>
          <description>We assessed the EFS of APL patients treated with retinoic acid receptor alpha (ATRA) and Arsenic Trioxide (ATO) based trial. Event-free survival (EFS) was defined as time from diagnosis to last follow-up or an event (relapse or death).</description>
          <population>There were 65 patients included in our study, including 35 in the DNR group and 30 in the DNR+Ara-C group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>die</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Side Effects</title>
        <description>Also, we compared the side effect and outcome between the two groups.To assessed whether Ara-C could be omitted when ATO and ATRA were used.</description>
        <time_frame>three years</time_frame>
        <population>There were 66 patients included in our study. One patient gave up treatment due to the economic reasons. Then the number of the patients were 65, including 35 in the DNR group and 30 in the DNR+Ara-C group.</population>
        <group_list>
          <group group_id="O1">
            <title>DNR+Ara-c (Ara-C Group)</title>
            <description>one group treated with DNR+Ara-C in consolidation</description>
          </group>
          <group group_id="O2">
            <title>DNR (No Ara-c Group)</title>
            <description>Only DNR was used in consolidation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Side Effects</title>
          <description>Also, we compared the side effect and outcome between the two groups.To assessed whether Ara-C could be omitted when ATO and ATRA were used.</description>
          <population>There were 66 patients included in our study. One patient gave up treatment due to the economic reasons. Then the number of the patients were 65, including 35 in the DNR group and 30 in the DNR+Ara-C group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>platelet transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>red blood cell transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Between May 2010 and December 2016, 65 consecutive paediatric (≤14years old) patients who were genetically confirmed with a new diagnosis of APL were admitted in our hospital.The follow-up of the patients was updated on Jan 2017 and included a median of 32 months (range, 1 to 79). The adverse event data were collected from the patient enrolled in our trials.The median period of time were 32 months (range, 1 to 79).</time_frame>
      <desc>All adverse events described were founded during the course of induction therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>All the Patients at Presentation</title>
          <description>Between May 2010 and December 2016, 65 consecutive paediatric (≤14 years of age) patients who were genetically confirmed with a new diagnosis of APL were admitted in our hospital.</description>
        </group>
        <group group_id="E2">
          <title>the Adverse Events Associated With ATRA</title>
          <description>There were 65 patients were treated with ATRA and ATO in induction.</description>
        </group>
        <group group_id="E3">
          <title>the Adverse Events Associated With ATO</title>
          <description>There were 65 patients were treated with ATRA and ATO in induction.</description>
        </group>
        <group group_id="E4">
          <title>Consolidation: IDA</title>
          <description>There were 65 patients were treated with IDA in consolidation. .</description>
        </group>
        <group group_id="E5">
          <title>Consolidation: ATO</title>
          <description>There were 65 patients were treated with ATO in consolidation.</description>
        </group>
        <group group_id="E6">
          <title>Consolidation: DNR (No Ara-c Group)</title>
          <description>There were 35 patients were treated with DNR in consolidation.</description>
        </group>
        <group group_id="E7">
          <title>Consolidation: DNR+Ara-c (Ara-C Group)</title>
          <description>There were 30 patients were treated with DNR+ARA-C in consolidation.</description>
        </group>
        <group group_id="E8">
          <title>Maintenance: ATRA+MTX+6-MP</title>
          <description>There were 65 patients were treated with maintenance.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>retinoic acid syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>intraocular bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>intracranial bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>mild partial splenic embolization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>retinoic acid syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>asymptomatic QTc prolongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>extremity oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bone ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin pigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>xiaofan Zhu</name_or_title>
      <organization>Department of pediatrics, Institute of Hematology and Blood Diseases Hospital.</organization>
      <phone>+86 22 23909001</phone>
      <email>xfzhu@ihcams.ac.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

